Alnylam
Phone: +1 617 551 8200
Fax: +1 617 551 8101
| Type | Public |
|---|---|
| Traded as | Nasdaq: ALNY Russell 1000 Component |
| Industry | Pharmaceutical |
| Founded | 2002 |
| Headquarters | Cambridge, Massachusetts, US |
| Key people | Yvonne Greenstreet, (CEO) |
| Revenue |  US $219.75 million (2019) US $74.91 million (2018) |
| Number of employees | 1,323 (2019) |
| Website | alnylam.com |
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
For detailed contact information visit location pages below.
Alnylam's locations around the world
Clinical Trials sponsored by Alnylam
-
Alnylam PharmaceuticalsReclutamentoDiabete mellito di tipo 2 (T2DM)Stati Uniti
-
Alnylam PharmaceuticalsReclutamento
-
Alnylam PharmaceuticalsReclutamentoAmiloidosi della tranhiretina con cardiomiopatiaStati Uniti
-
Alnylam PharmaceuticalsReclutamentoDiabete mellito di tipo 2 (T2DM) | Volontari sani obesi o in sovrappesoStati Uniti, Polonia, Canada, Chile, Argentina, Germania
-
Alnylam PharmaceuticalsReclutamentoPolineuropatia | Amiloidosi ereditaria mediata dalla transtiretina (hATTR).Olanda, Spagna, Stati Uniti, Germania, Portogallo, Francia, Italia
-
Alnylam PharmaceuticalsReclutamentoPorfiria epatica acutaBelgio, Francia, Germania, Spagna, Regno Unito, Stati Uniti, Italia, Svezia, Taiwan, Svizzera
-
Alnylam PharmaceuticalsAttivo, non reclutanteAmiloidosi ereditaria correlata alla transtiretina | Stato di portatore asintomaticoFrancia
-
Alnylam PharmaceuticalsCompletatoAmiloidosi da transtiretina (ATTR) con cardiomiopatiaStati Uniti, Regno Unito, Brasile, Portogallo, Argentina, Giappone, Taiwan, Australia, Francia, Cechia, Polonia, Italia, Danimarca, Olanda, Bulgaria, Hong Kong, Messico, Nuova Zelanda, Corea del Sud, Svezia, Belgio, Chile
-
Alnylam PharmaceuticalsAttivo, non reclutanteAmiloidosi da transtiretina (ATTR) con cardiomiopatiaStati Uniti, Lettonia, Germania, Spagna, Regno Unito, Canada, Giappone, Portogallo, Austria, Francia, Australia, Belgio, Ungheria, Corea del Sud, Danimarca, Olanda, Argentina, Croazia, Cechia, Irlanda, Israele, Libano, Lituania, Malaysi... e altro ancora
-
Alnylam PharmaceuticalsCompletato